EGFR and small cell lung carcinoma: In vitro studies using breast and small cell lung cancer cell lines, have shown that INCB3619 reduced the cleavage of HER2 and amphiregulin, thereby sensitising cells to the EGFR tyrosine kinase inhibitor, gefintinib or a dual EGFR/HER2 inhibitor, GW2974 [98–100].